Radiation oncologist

Radiation Oncology Expert and Cancer Researcher Dr. Daniel Vanderbilt Joins Associated Medical Professionals of NY, an Affiliate of U.S. Urology Partners

Retrieved on: 
Tuesday, February 20, 2024
Technology, Biotechnology, Health, Robotics, Radiology, Pharmaceutical, Surgery, Oncology, Research, Medical Devices, General Health, Hospitals, Science, Clinical Trials, Hospital, Philosophy, Doctor of Philosophy, MD, Physician, Cancer, Prostate, Clinical research, Weill Cornell Medicine, Lung, Radiation oncologist, Breast, NMS, Patient, A.M.P, Radiation, Corporation, MultiCare Health System

is pleased to announce that Daniel B. Vanderbilt, MD, PhD , has joined its care team .

Key Points: 
  • is pleased to announce that Daniel B. Vanderbilt, MD, PhD , has joined its care team .
  • Specialty trained in radiation oncology with a doctorate in cancer cell biology, Dr. Vanderbilt has vast experience in researching, diagnosing and treating cancers utilizing the latest technologies.
  • The Associated Medical Professionals of NY multi-specialty practice spans 19 locations in Central New York, including ten offices and nine hospitals.
  • Dr. Vanderbilt will be based in A.M.P.’s office at 2 Ellinwood Drive in New Hartford, NY 13413.

Varian Receives FDA 510(k) Clearance for TrueBeam and Edge Radiotherapy Systems Featuring HyperSight Imaging Solution

Retrieved on: 
Thursday, February 29, 2024
Ethos, Acquisition, PALO, Neoplasm, Anxiety, Assistant, FDA, Food, Radiation, EDGE, Siemens Healthineers, Cancer Institute, Medical examiner, Scale (music), Radiation oncologist, Lenox Hill Hospital, CBCT, Patient, Movement, Medical imaging

HyperSight is designed to enhance accuracy in delivering radiotherapy treatments, with the goal of effective protection of healthy tissues

Key Points: 
  • HyperSight is designed to enhance accuracy in delivering radiotherapy treatments, with the goal of effective protection of healthy tissues
    PALO ALTO, Calif., Feb. 29, 2024 /PRNewswire/ -- Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for TrueBeam and Edge radiotherapy systems featuring HyperSight imaging solution.
  • By extending the groundbreaking HyperSight imaging solution optional feature to the TrueBeam and Edge systems, Varian continues to revolutionize imaging inside the radiotherapy treatment room and adds new capabilities and workflows across the entire suite of linear accelerators.
  • HyperSight on TrueBeam and Edge acquires images for all anatomical sites with a 50% faster gantry rotation, significantly reducing acquisition time.
  • VARIAN, TRUEBEAM, EDGE, ETHOS, HALCYON, HYPERSIGHT are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat.

INTEGRATED ONCOLOGY NETWORK and IMPERIAL VALLEY RADIATION ONCOLOGY WELCOME RADIATION ONCOLOGIST DR. YUJI SEO TO THEIR MEDICAL TEAM

Retrieved on: 
Thursday, February 1, 2024
ION, Breast cancer, Research, Case Western Reserve University, Patient, Head, Lung cancer, Radiation oncologist, Radiation therapy, Education, Osaka University, Medical imaging

NASHVILLE, Tenn., Feb. 1, 2024 /PRNewswire/ -- Integrated Oncology Network (ION), with Imperial Valley Radiation Oncology, is proud to announce the addition of Radiation Oncologist Dr. Yuji Seo to our medical team in California. 

Key Points: 
  • NASHVILLE, Tenn., Feb. 1, 2024 /PRNewswire/ -- Integrated Oncology Network (ION), with Imperial Valley Radiation Oncology, is proud to announce the addition of Radiation Oncologist Dr. Yuji Seo to our medical team in California.
  • Welcoming experienced, dedicated Radiation Oncologist, Dr. Yuji Seo to the Imperial Valley Region!
  • Dr. Seo is looking forward to joining the team and providing full-time radiation oncology services to the community stating, "I'm excited to join ION and Imperial Valley Radiation Oncology.
  • Contact Imperial Valley Radiation Oncology to learn more about his services.

New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery

Retrieved on: 
Thursday, May 11, 2023
ICAD, Face, Neoplasm, Mohs surgery, Cancer, Skin, Scalp, Nose, Incidence, Wound healing, Journal, MD, Inc., Patient, Mohs, NMSC, Financial toxicity, Recurrence, Radiation oncologist, Safety, Disease, Medical imaging, Pharmaceutical industry

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling new long-term real-world research confirms Xoft Skin eBx is as safe and effective as Mohs surgery for the treatment of non-melanoma skin cancer (NMSC).

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling new long-term real-world research confirms Xoft Skin eBx is as safe and effective as Mohs surgery for the treatment of non-melanoma skin cancer (NMSC).
  • In the longest-term study of Xoft Skin eBx to-date, published in the Journal of Contemporary Brachytherapy , 98.9% of patients remained recurrence-free at a median follow-up of 7.6 years.
  • Using a small surface applicator placed on the skin, Xoft Skin eBx targets cancer directly over a short series of office visits lasting a few minutes each.
  • “Xoft Skin eBx arms clinicians with a safe and effective alternative to surgery that can be seamlessly integrated in virtually any clinical setting.

New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023

Retrieved on: 
Thursday, January 19, 2023
Oncology, Health, Surgery, Genetics, Research, Science, Biotechnology, American Society of Clinical Oncology, NPV, SCCA, Poster, ASCO, University, CRC, MRD, GI, Stomach, Fred Hutchinson Cancer Research Center, DNA, Sequence, Nucleic acid thermodynamics, Radiation oncologist, Anal cancer, NTRA, Nominal interest rate, Patient, Society, University of Washington School of Medicine, Pharmaceutical industry, Medical imaging, Medical device, Nature Medicine, Natera

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the American Society of Clinical Oncology's 2023 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 19 – 21, 2023 in San Francisco, California.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the American Society of Clinical Oncology's 2023 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 19 – 21, 2023 in San Francisco, California.
  • The presentations will highlight findings on the utility of Signatera for MRD assessment in colorectal (CRC), esophageal, gastric and anal cancers, in a total of five presentations.
  • “On the heels of the groundbreaking CIRCULATE-Japan results just released, we are excited to share additional data further underscoring the real-world utility of Signatera in GI cancers,” said Solomon Moshkevich, general manager of oncology at Natera.
  • Additionally, analysis of whole exome sequencing data from all 251 patients found significant genomic heterogeneity, further highlighting the value of a personalized and tumor-informed approach to ctDNA testing.

Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV

Retrieved on: 
Wednesday, January 4, 2023
Radiation oncologist, Patient, Oncology, IV, Degenerative disease, Vomiting, CR, Risk, CINV, Pharmaceutical industry

Using data from a previously reported phase 3 trial, the analysis classified patients into 3 groups based on their response during the first chemotherapy cycle: CR, short-term CINV (1-2 days), and extended CINV (3-5 days).

Key Points: 
  • Using data from a previously reported phase 3 trial, the analysis classified patients into 3 groups based on their response during the first chemotherapy cycle: CR, short-term CINV (1-2 days), and extended CINV (3-5 days).
  • The analysis indicated that patients who experienced CR in their first cycle had a 93% or higher CR rates in subsequent cycles.
  • Comparing patients with short-term CINV and extended CINV in cycle 1, recurrent CINV occurred in 30.6% and 69.5% of subsequent cycles, respectively (p
  • With close monitoring during the first chemotherapy cycle, clinicians can use the patient’s response data to optimize antiemetic prophylaxis when extended CINV does occur.

Elaine Y. Weng, MD, is recognized by Continental Who's Who

Retrieved on: 
Monday, November 28, 2022
Hobby, University of Colorado School of Medicine, Radiation oncologist, Museum, Radiation therapy, David Geffen School of Medicine at UCLA, University, American Board of Radiology, Health care, Multimedia, Cooking, Patient, Radiation, Ministry of Health (New South Wales), MD, Consultant, UCLA, American Board of Commissioners for Foreign Missions, Cancer, Family, Ronald Reagan UCLA Medical Center, Harbor–UCLA Medical Center, ABR, Continental, Strategic planning, Stanford University, Medical imaging, Medicine, Biology, Radiology

Dr. Elaine Y. Weng is an experienced Radiation Oncologist with 20 years of experience in the field.

Key Points: 
  • Dr. Elaine Y. Weng is an experienced Radiation Oncologist with 20 years of experience in the field.
  • In 2010, Dr. Weng joined Mountain Radiation Oncology Consultants, where she still treats patients today.
  • She is the Chairman of the Board of the Children's Museum of Denver and Secretary of Strategic Planning for the Breakthrough National Collaborative.
  • Dr. Weng first studied at Stanford University, where she earned a Bachelor of Science degree and Master of Science degree in Biology.

Arizona Oncology Cancer Center working with NexCore Group on new cancer treatment center

Retrieved on: 
Thursday, October 6, 2022
Physician, Caregiver, HDR, Radiation oncologist, Healthcare Facilities Accreditation Program, Disease, Radiation, LINAC, Patient, Hospital, Hematology-Oncology and Stem Cell Transplantation Research Center, Urology, Modern Healthcare, Cancer, CT, Google Images, Radiation therapy, Real estate development, Breast cancer, Nutritionist, Oncology, Pharmacist, Surgical oncology, FDA, PET-CT, Medical imaging, Medicine, Hematology, Research, Medicine

DENVER, Oct. 6, 2022 /PRNewswire/ -- This past weekend, national health care, life sciences and senior housing real estate developer NexCore Group, in collaboration with Arizona Oncology, broke ground on a state-of-the-art cancer treatment center in Prescott, Ariz. located at 5430 Landmark Lane. Arizona Oncology, one of the largest medical groups in Arizona devoted exclusively to cancer care, and NexCore will develop a new 22,105-square-foot facility anticipated to open in September 2023. Once operational, the Arizona Oncology Cancer Center will offer patients in the region convenient access to the latest cancer treatment services and technologies.

Key Points: 
  • Once operational, the Arizona Oncology Cancer Center will offer patients in the region convenient access to the latest cancer treatment services and technologies.
  • The Arizona Oncology Cancer Center is currently located at 3188 N. Windsong Dr. but will relocate once this project is complete.
  • "Arizona Oncology is committed to evolving our practices to best fit the needs of our patients," said Iyad Hamarneh, medical oncologist with Arizona Oncology.
  • When completed, our cancer center will be the only practice in the quad-city region that will offer medical oncology, radiation oncology and hematology services for our community."

Dr. Elaine Y. Weng, MD, is recognized by Continental Who's Who

Retrieved on: 
Tuesday, August 23, 2022
Health care, University, University of Colorado School of Medicine, Cancer, Ministry of Health (New South Wales), Consultant, Continental, American Board of Commissioners for Foreign Missions, David Geffen School of Medicine at UCLA, Museum, Board, ABR, Radiation, Strategic planning, Hobby, Cooking, Radiation therapy, American Board of Radiology, Multimedia, Radiation oncologist, MD, Stanford University, Ronald Reagan UCLA Medical Center, UCLA, Harbor–UCLA Medical Center, Family, Patient, Medical imaging, Medicine, Radiology, Medicine, Medicine, Biology

With over 20 years in the medical field, Dr. Elaine Y. Weng is an experienced Radiation Oncologist.

Key Points: 
  • With over 20 years in the medical field, Dr. Elaine Y. Weng is an experienced Radiation Oncologist.
  • In 2010, Dr. Weng joined Mountain Radiation Oncology Consultants, where she still treats patients today.
  • She is the Chairman of the Board of the Children's Museum of Denver and Secretary of Strategic Planning for the Breakthrough National Collaborative.
  • In recognition of her professional excellence, Dr. Weng was recognized in a profile feature from Health News Today.

TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology

Retrieved on: 
Monday, July 11, 2022
Private Securities Litigation Reform Act, Safety, Associate professor, Harvard Medical School, Radiation therapy, JAMA Oncology, Analysis, COVID-19, Antigen, Therapy, Annual report, Radiation oncologist, Securities Exchange Act of 1934, Associate, Dana–Farber Cancer Institute, MAGE-A1, Immunotherapy, MIT, Virology, Financial condition report, IND, Company, Hospital, CD8, Nasdaq, Cancer, Technology, TCR, Research, Center, GLOBE, Patient, HLA, Hematopoietic stem cell transplantation, Harvard University, Cell, Result, Clinical trial, Vaccine, Pharmaceutical industry, Neurology, Brigham

WALTHAM, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the publication of a peer-reviewed article titled, “Tissue-resident Memory and Circulating T cells are Early Responders to Pre-surgical Cancer Immunotherapy” in the journal Cell. The data highlight the ability of TScan’s unbiased, genome-wide screening technology to identify novel target antigens and highly active TCRs for adoptive T cell cancer therapies, including the TCR that has now become the Company’s therapeutic candidate TSC-204-C07 for MAGE-A1.

Key Points: 
  • Single cell analysis revealed that tumor-infiltrating CD8 T cells that expanded upon treatment with checkpoint blockade exhibited specific and identifiable gene expression signatures.
  • Analysis of the TCRs of these expanded T cells using TScans screening technology revealed several novel targets.
  • In one responding patient, two different T cell clones recognized the same novel C*07:02-restricted epitope on the cancer/testis antigen MAGE-A1, and both TCRs exhibited strong anti-cancer activity.
  • The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.